Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

This phase 2, single‐arm trial is evaluating the combination of pembrolizumab and metronomic cyclophosphamide in patients with refractory, unresectable non-ocular stage III/IV melanoma. Sponsored by UC Irvine, the study targets patients who have failed prior checkpoint inhibitor therapy.